Payment overview · 2025
General Payments
$1,172.24
51 reported records · 16 companies
Healthcare provider profile · identity verified
Daniel V Arnold, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BOSTON, MA · NPI 1679764773
Verified facts
What the public records show
CMS Open Payments records show Daniel V Arnold, M.D. received $1,172.24 in general payments during 2025 across 51 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $238.22 | 20.3% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $162.63 | 13.9% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $110.12 | 9.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.68 | 8.3% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $84.85 | 7.2% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $79.34 | 6.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.11 | 6.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.62 | 5.6% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.06 | 5.0% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $43.61 | 3.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $43.53 | 3.7% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.02 | 2.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.18 | 1.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.42 | 1.8% | 1 | 2025 |
| Lucid Diagnostics Inc. | Unresolved — no canonical attribution shown | $19.65 | 1.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.20 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,172.24 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $162.63 | 3 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $110.12 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $99.67 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $84.85 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $79.34 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $74.22 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $72.65 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $69.50 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $68.01 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $58.06 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.67 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.04 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $43.61 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $43.53 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.72 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 187 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 142 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
98 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
142 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
187 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
43 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 712 | 222 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 646 | 212 |
| Levothyroxine Sodium | Levothyroxine Sodium | 568 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 532 | 162 |
| Lisinopril | Lisinopril | 450 | 134 |
| Omeprazole | Omeprazole | 337 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 327 | 101 |
| Losartan Potassium | Losartan Potassium | 295 | 105 |
| Trazodone Hcl | Trazodone Hcl | 260 | 79 |
| Prednisone | Prednisone | 259 | 136 |
| Escitalopram Oxalate | Escitalopram Oxalate | 247 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 72 |
| Lorazepam | Lorazepam | 237 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 228 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 73 |
| Sertraline Hcl | Sertraline Hcl | 204 | 53 |
| Eliquis | Apixaban | 187 | 53 |
| Allopurinol | Allopurinol | 177 | 49 |
| Gabapentin | Gabapentin | 172 | 51 |
| Furosemide | Furosemide | 167 | 54 |
| Tramadol Hcl | Tramadol Hcl | 162 | 58 |
| Metformin Hcl Er | Metformin Hcl | 156 | 49 |
| Simvastatin | Simvastatin | 156 | 52 |
| Alprazolam | Alprazolam | 146 | 37 |
| Ozempic | Semaglutide | 142 | 28 |
| Celecoxib | Celecoxib | 126 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 57 |
| Valsartan | Valsartan | 118 | 31 |
| Cephalexin | Cephalexin | 117 | 93 |
| Metformin Hcl | Metformin Hcl | 116 | 43 |
| Azithromycin | Azithromycin | 109 | 95 |
| Finasteride | Finasteride | 109 | 36 |
| Atenolol | Atenolol | 107 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 104 | 82 |
| Doxycycline Hyclate | Doxycycline Hyclate | 98 | 66 |
| Synthroid | Levothyroxine Sodium | 98 | 31 |
| Pregabalin | Pregabalin | 88 | 17 |
| Potassium Chloride | Potassium Chloride | 87 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 30 |
| Bupropion Xl | Bupropion Hcl | 82 | 25 |
| Montelukast Sodium | Montelukast Sodium | 82 | 30 |
| Jardiance | Empagliflozin | 81 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 19 |
| Alendronate Sodium | Alendronate Sodium | 77 | 28 |
| Mirtazapine | Mirtazapine | 76 | 26 |
| Warfarin Sodium | Warfarin Sodium | 76 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 19 |
| Meloxicam | Meloxicam | 74 | 21 |
| Mounjaro | Tirzepatide | 74 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 36 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | 20 |
| Famotidine | Famotidine | 58 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 16 |
| Irbesartan | Irbesartan | 53 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 14 |
| Donepezil Hcl | Donepezil Hcl | 51 | 14 |
| Xarelto | Rivaroxaban | 51 | 17 |
| Carvedilol | Carvedilol | 50 | 16 |
| Diazepam | Diazepam | 50 | 14 |
| Nifedipine Er | Nifedipine | 50 | 15 |
| Buspirone Hcl | Buspirone Hcl | 49 | 13 |
| Spironolactone | Spironolactone | 49 | 16 |
| Clonazepam | Clonazepam | 48 | 14 |
| Amoxicillin | Amoxicillin | 46 | 36 |
| Methadone Hcl | Methadone Hcl | 45 | suppressed |
| Mupirocin | Mupirocin | 45 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 43 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 38 |
| Hydrocortisone | Hydrocortisone | 41 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | 15 |
| Valacyclovir | Valacyclovir Hcl | 41 | 28 |
| Methylprednisolone | Methylprednisolone | 40 | 36 |
| Nystatin | Nystatin | 39 | 21 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 36 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 30 |
| Cefdinir | Cefdinir | 35 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Ezetimibe | Ezetimibe | 29 | 11 |
| Ketoconazole | Ketoconazole | 29 | 12 |
| Torsemide | Torsemide | 29 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Erythromycin | Erythromycin Base | 27 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 19 |
| Naproxen | Naproxen | 25 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 23 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 15 |
| Digoxin | Digoxin | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Colchicine | Colchicine | 21 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Estradiol | Estradiol | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | 12 |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Lamictal | Lamotrigine | 14 | suppressed |
| Lamotrigine Er | Lamotrigine | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Levoxyl | Levothyroxine Sodium | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,172.24 · 51 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, COMIRNATY, ELIQUIS, FARXIGA, GVOKE HYPOPEN, INSPIRE, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, ONPATTRO, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error